Interview with Carlos Kiffer, President, GC-2
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
Address: Av. Nações Unidas, 12.399, 12º andar, cj 125 A, Edifício Landmark CEP 04578-000, São Paulo – SP,Brazil
Tel: (11) 3528 7406
Web: http://www.gcdois.com.br/
GC-2, in tune with the surge in R&D for pharmaceutical products in the region, provides intelligent solutions for this interdisciplinary scenario.
The natural growth of pharmaceuticals in the region, including herbal medicines and biotechnology products, has caused a parallel demand for project management. However, GC-2 is not just one more consulting firm. We bring the Project Management Office concept to pharmaceutical R&D.
In order to strengthen the strategic decision making process in pharmaceutical drug and product development, GC-2 offers its clients alternatives for the technical and commercial scientific monitoring of their developments:
Technical and scientific viability and patentability, Conceptualization & positioning, Structuring & management, Production and quality insurance interface, Pre-clinical pharmacological development interface, Pre-clinical toxicological development interface, Clinical development, Public agency interface, Antimicrobial development
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
Fabio Bussinger, partner-director of the Pharmaceutical Institute of Operational Governance (IFGO) in Brazil, documents the market needs that prompted him to set up Benchmarking Operational Competitiveness (BCO) Farma, a long-awaited…
Lauro Moretto, Emeritus President of the Brazilian Academy of Pharmaceutical Sciences and former Executive Vice-President of Sindusfarma provides insights into the main changes that have impacted Brazil’s pharmaceutical field over…
In an exclusive interview, Jarbas Barbosa da Silva, Director-President of the Brazilian Health Regulatory Agency (ANVISA), discusses some of the key specificities of the Brazilian market and highlights some of…
Dr. Wilson Pedreira, executive director of the Oncology and Hematology Center of the Albert Einstein Philanthropic Society in Brazil provides insights into the innovative healthcare model implemented in this cutting…
PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of…
The government recently released the ‘BrasilMaior’ plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
The government recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
We met recently with Minister Pimentel when he launched his BrasilMaior plan, whose slogan was “Innovate to Compete. Compete to Grow.” If you had to make a recommendation to increase…
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re…
See our Cookie Privacy Policy Here